Astellas 5-Year Plan & Takeda Psoriasis Drug Success
Infographic: Astellas CEO Unveils 5-Year Plan; Takeda Beats BMS in Psoriasis Trial
Key Highlights
Astellas CEO reveals a $1.3B cost-saving plan & R&D focus. Takeda’s zasocitinib shows superior efficacy over BMS’s Sotyktu in a key psoriasis trial.
Astellas CEO Naoki Okamura has unveiled a new five-year strategy, including a 200 billion yen ($1.3 billion) cost-savings program, aiming to streamline operations and internalize R&D. This strategic shift comes as Takeda scored a significant win in a Phase 3 trial, where its psoriasis drug zasocitinib surpassed Bristol Myers Squibb’s Sotyktu.
Astellas Charts New 5-Year Course
Astellas’ CEO Naoki Okamura detailed a comprehensive five-year plan focused on efficiency and innovation. The strategy includes a substantial 200 billion yen ($1.3 billion) cost-savings initiative.
- The plan emphasizes internalizing core R&D capabilities.
- It also prioritizes adopting new technologies and centralizing functions for a more streamlined organization.
Takeda’s Psoriasis Drug Outperforms BMS
Takeda’s TYK2 inhibitor, zasocitinib, demonstrated superior efficacy in a Phase 3 head-to-head trial for moderate-to-severe plaque psoriasis. It outperformed Bristol Myers Squibb’s Sotyktu across key metrics.
- Over 35% of patients achieved complete skin clearance (PASI 100) by week 16 with zasocitinib.
- This response rate was more than 2.5 times higher than that observed with Sotyktu.
- All key secondary endpoints were also successfully met, reinforcing zasocitinib’s potential.
China Bridge Program Expands, WuXi AppTec Listed
RA Capital’s Swiftbridge program, launched a year ago, is expanding its reach. Initially providing early-stage portfolio companies access to China’s clinical trial infrastructure, it now includes business development and early-stage discovery project management.
Separately, WuXi AppTec was added to the Pentagon’s updated list of “Chinese military companies,” a move the CDMO giant called a “mistake.” This listing could trigger restrictions under the BIOSECURE Act.
Takeda also reported a $2.5 billion legal charge in its fiscal 2025 earnings due to a federal jury finding the company liable in a class-action pay-for-delay lawsuit. The company plans to appeal this verdict, which shifted its reported income from a net profit to a loss.
Further industry news includes XtalPi securing a $400 million anti-GPCR deal with an undisclosed multinational pharmaceutical company. Laekna Therapeutics also outlicensed its PI3K inhibitor to Vasque Bio.